CHA Vaccine Institute Co. Ltd.

AriBioLab Co.,Ltd. is a research-oriented biotechnology company that develops vaccine products for infectious and chronic diseases. Its pipeline includes a third-generation prophylactic HBV vaccine in Phase IIb planning for hepatitis B prevention, an adjuvanted HBV therapeutic vaccine in Phase I/IIa for chronic hepatitis B treatment, and a VZV (shingles) vaccine in Phase I for the prevention of herpes zoster. It also develops a seasonal influenza vaccine, a quadrivalent next-generation flu vaccine, a TB booster vaccine, recombinant MBL for infectious disease suppression, and TLR ligand-based immunostimulants. The company was formerly known as CHA Vaccine Research Institute and changed its name to AriBioLab Co.,Ltd. in May 2026. Incorporated in 2000, it is headquartered in Seongnam-si, South Korea.